Cargando…

Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy

BACKGROUND: In Italy HPV vaccination with the quadrivalent vaccine (Gardasil(®)) is offered actively and free of charge to girls aged 12 since 2007. A nine-valent vaccine (Gardasil 9(®)) received the European market authorization in 2015 to protect, with only 2 doses, against around 90% of all HPV p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mennini, Francesco Saverio, Bonanni, Paolo, Bianic, Florence, de Waure, Chiara, Baio, Gianluca, Plazzotta, Giacomo, Uhart, Mathieu, Rinaldi, Alessandro, Largeron, Nathalie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5504713/ https://www.ncbi.nlm.nih.gov/pubmed/28701899 http://dx.doi.org/10.1186/s12962-017-0073-8

Ejemplares similares

Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria
por: Boiron, L., et al.
Publicado: (2016)

Cost-effectiveness analysis of a vaccination program for the prevention of herpes zoster and post-herpetic neuralgia in adults aged 50 and over in Germany
por: Préaud, Emmanuelle, et al.
Publicado: (2015)

Economic Burden of Human Papillomavirus-Related Diseases in Italy
por: Baio, Gianluca, et al.
Publicado: (2012)

Correction: Economic Burden of Human Papillomavirus-Related Diseases in Italy
por: Baio, Gianluca, et al.
Publicado: (2013)

Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in Europe
por: Uhart, Mathieu, et al.
Publicado: (2016)

HPV Vaccination during the COVID-19 Pandemic in Italy: Opportunity Loss or Incremental Cost
por: Mennini, Francesco Saverio, et al.
Publicado: (2022)

Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States
por: Gee, Julianne, et al.
Publicado: (2016)

Cost-effectiveness of switching from trivalent to quadrivalent inactivated influenza vaccines for the at-risk population in Italy
por: Mennini, Francesco Saverio, et al.
Publicado: (2018)

Prevalence of high-risk HPV genotypes, categorised by their quadrivalent and nine-valent HPV vaccination coverage, and the genotype association with high-grade lesions
por: Paz-Zulueta, María, et al.
Publicado: (2018)

Epidemiology and costs of cervical cancer screening and cervical dysplasia in Italy
por: Rossi, Paolo Giorgi, et al.
Publicado: (2009)

A comparative analysis of the epidemiological impact and disease cost-savings of HPV vaccines in France
por: Bresse, Xavier, et al.
Publicado: (2013)

Spotlight on the 9-valent HPV vaccine
por: Lopalco, Pier Luigi
Publicado: (2016)

Systematic review of cost-effectiveness analyses for combinations of prevention strategies against human papillomavirus (HPV) infection: a general trend
por: Gervais, Frédéric, et al.
Publicado: (2017)

Economic burden of schizophrenia in Italy: a probabilistic cost of illness analysis
por: Marcellusi, Andrea, et al.
Publicado: (2018)

Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study
por: Cody, Palmer, et al.
Publicado: (2021)

Socio-economic impact of epilepsy in Italy
por: Mennini, Francesco Saverio, et al.
Publicado: (2022)

Cutaneous HPV and alpha-mucosal 9-valent HPV sero-status associations
por: Rahman, Shams, et al.
Publicado: (2017)

Real-Life Safety Profile of the 9-Valent HPV Vaccine Based on Data from the Puglia Region of Southern Italy
por: Di Lorenzo, Antonio, et al.
Publicado: (2022)

Loss of chance associated with sub-optimal HPV vaccination coverage rate in France
por: Uhart, Mathieu, et al.
Publicado: (2017)

Estimation of the epidemiological burden of HPV-related anogenital cancers, precancerous lesions, and genital warts in women and men in Europe: Potential additional benefit of a nine-valent second generation HPV vaccine compared to first generation HPV vaccines
por: Hartwig, Susanne, et al.
Publicado: (2015)

Estimating the clinical benefits of vaccinating boys and girls against HPV-related diseases in Europe
por: Marty, Rémi, et al.
Publicado: (2013)

The Impact of 9-Valent HPV Vaccination on Couple Infertility Prevention: A Comprehensive Review
por: Ciavattini, Andrea, et al.
Publicado: (2021)

Costs and Cost-Effectiveness of 9-Valent Human Papillomavirus (HPV) Vaccination in Two East African Countries
por: Kiatpongsan, Sorapop, et al.
Publicado: (2014)

Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease
por: Serrano, Beatriz, et al.
Publicado: (2012)

Estimation of the number of HCV-positive patients in Italy
por: Gardini, Ivan, et al.
Publicado: (2019)

An Analysis of the Social and Economic Costs of Breast Cancer in Italy
por: Mennini, Francesco Saverio, et al.
Publicado: (2021)

Cost-effectiveness analysis of Vaborem in Carbapenem-resistant Enterobacterales (CRE) -Klebsiella pneumoniae infections in Italy
por: Mennini, Francesco Saverio, et al.
Publicado: (2021)

Cost-effectiveness evaluations of the 9-Valent human papillomavirus (HPV) vaccine: Evidence from a systematic review
por: Mahumud, Rashidul Alam, et al.
Publicado: (2020)

Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong
por: Cheung, Tak Hong, et al.
Publicado: (2023)

Use of 9-Valent Human Papillomavirus (HPV) Vaccine: Updated HPV Vaccination Recommendations of the Advisory Committee on Immunization Practices
por: Petrosky, Emiko, et al.
Publicado: (2015)

Bayesian models for cost-effectiveness analysis in the presence of structural zero costs
por: Baio, Gianluca
Publicado: (2014)

Risk of unexpected uterine leiomyosarcoma during laparoscopic procedures: Experience from a single tertiary institute in Italy
por: Surace, Alessandra, et al.
Publicado: (2021)

Clinical guideline for 9-valent HPV vaccine: Korean Society of Gynecologic Oncology Guideline
por: Min, Kyung-Jin, et al.
Publicado: (2019)

Correction: Cost-effectiveness evaluations of the 9-Valent human papillomavirus (HPV) vaccine: Evidence from a systematic review
por: Mahumud, Rashidul Alam, et al.
Publicado: (2023)

HPV and Cytology Testing in Women Undergoing 9-Valent HPV Opportunistic Vaccination: A Single-Cohort Follow Up Study
por: De Vincenzo, Rosa, et al.
Publicado: (2021)

The costs of headache disorders
por: Mennini, Francesco Saverio, et al.
Publicado: (2015)

The burden of seasonal influenza in Italy: A systematic review of influenza‐related complications, hospitalizations, and mortality
por: Giacchetta, Irene, et al.
Publicado: (2021)

Assessing the epidemiological impact on cervical cancer of switching from 4-valent to 9-valent HPV vaccine within a gender-neutral vaccination programme in Switzerland
por: Kind, André B., et al.
Publicado: (2020)

Optimizing diagnostic algorithms to advance Hepatitis C elimination in Italy: A cost effectiveness evaluation
por: Marcellusi, Andrea, et al.
Publicado: (2021)

How can the results of Health Technology Assessment (HTA) evaluations applied to vaccinations be communicated to decision-makers and stakeholders? The ISPOR Rome Chapter Project
por: GASPARINI, R., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_mr36dhtmibfv195ia88qfkvfeq